MTNR1B

Across TCGA pan-cancer cohorts, MTNR1B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTNR1B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher MTNR1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTNR1B expression acts as an unfavorable survival marker.

UVM, DLBC, and ESCA are the cancer types where MTNR1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	II,III,IV	0.218	0.718	.006	24	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
ESCA	DFS	Median	II,III,IV	0.173	0.525	.017	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	DFS	Median	All	0.071	0.288	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTNR1B–UVM (OS)

Open the UVM breakdown →